Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984899 | 0.81 | TP53 (0.39) | TP53KMT2AMEN1BRD4MAPT | |
| SCHEMBL4982293 | 0.72 | POLB (0.32) | — | |
| SCHEMBL4981019 | 0.70 | — | — | |
| SCHEMBL4980980 | 0.69 | TP53 (0.41) | TP53KMT2AMEN1MAPTNPC1 | |
| SCHEMBL14188880 | 0.69 | PDE2A (0.31) | — | |
| SCHEMBL4983743 | 0.68 | TP53 (0.36) | TP53KMT2AMEN1MAPTCSF1R | |
| SCHEMBL12191689 | 0.66 | CRHBP (0.41) | KMT2AMEN1MAPT | |
| SCHEMBL22276844 | 0.64 | BTK (0.41) | TP53KMT2AMEN1BRD4MAPT | |
| SCHEMBL14402984 | 0.64 | TOP2A (0.33) | — | |
| SCHEMBL17150196 | 0.63 | NPY1R (0.32) | TP53KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1847535-A1 | 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1847535-A1 | 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | TPH1, HTR1D, HTR1B | TP53 1745/4885KMT2A 740/4885MEN1 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.